On October 31, 2022 OncoBone Ventures reported the company attended 34th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain on October 26 – 28 (Press release, OncoBone Ventures, OCT 31, 2022, View Source [SID1234636480]). In the Symposium Tiina Kähkönen, CSO of OncoBone Ventures presented a poster titled "Neutralizing Antibody for S100A8/A9 Soil Sensing Signal to Prevent Metastatic Disease" (you can watch the presentation from the following link: ENA presentation).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster was prepared in collaboration with Okayama University. It shows a summary of the preclinical work demonstrating a role for S100A8/A9 and its receptors in metastasis of melanoma, breast and lung cancer, and development of OBP-001, a neutralizing monoclonal antibody targeting S100A8/A9 that prevents formation of lung metastases in melanoma and breast cancer animal models.

Tiina Kähkönen, CSO of OncoBone Ventures says: "Based on current scientific evidence S100A8/A9 is a potential osteoimmuno-oncology (OIO) target for patients with bone metastases. We will continue by evaluating efficacy of OBP-001 in breast cancer bone metastasis models and are excited to share the progress in future scientific events."